Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113439 | 0.87 | DGAT1 (0.38) | DGAT1BRD4CREBBP | |
| SCHEMBL2600599 | 0.86 | DGAT1 (0.35) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL2112307 | 0.85 | DGAT1 (0.35) | DGAT1BRD4CREBBP | |
| SCHEMBL2113169 | 0.82 | DGAT1 (0.39) | DGAT1BRD4CREBBP | |
| SCHEMBL2111836 | 0.82 | DGAT1 (0.37) | DGAT1BRD4CREBBP | |
| SCHEMBL2600605 | 0.81 | DGAT1 (0.41) | DGAT1BRD4CREBBP | |
| SCHEMBL2600596 | 0.81 | DGAT1 (0.40) | DGAT1BRD4CREBBP | |
| SCHEMBL2113255 | 0.80 | DGAT1 (0.36) | DGAT1BRD4CREBBP | |
| SCHEMBL2112572 | 0.79 | DGAT1 (0.35) | DGAT1BRD4CREBBP | |
| SCHEMBL2114061 | 0.78 | DGAT1 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008150914-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | DGAT1 3455/4885BRD4 92/4885CREBBP 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.